Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >= 2 years
History of other malignancy within 2 years prior to screening
Participants with other active malignancy in the past 3 years excluding in situ tumors
Any other current or previous malignancy within 3 years except protocol allowed malignancies
Past or present malignancy within the last 5 years.
History of another malignancy within 3 years of the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
History of malignancy other than MM within the past 3 years
Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years.
History of malignancy other than B-NHL within the past 3 years with the exception of:
History of other active malignancy within past 2 years.
Prior other malignancy within 2 years (except for in situ disease, which is permissible).
Patients who have a history of another primary malignancy that has been diagnosed or required therapy within 3 years before randomization.
Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > 12 months prior and/or bone marrow transplant > 2 years prior
Active malignancy (other than melanoma) or a prior malignancy within the past 3 years
Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization.
Other malignancy requiring treatment in the prior 2 years
History of malignancy other than NSCLC within 2 years prior to screening
Has history of other active malignancy within 3 years prior to enrollment, except:
Patients must not have received treatment for another malignancy within 3 years of enrollment
Prior malignancy or therapy for a malignancy within 3 years
Participants with presence of other active malignancy within 2 years of study entry; participants with history of prior malignancy treated with curative intent and achieved CR within 2 years are eligible.
Other malignancy within 2 years prior to screening, with some exceptions
Active malignancy besides NSCLC within 3 years prior to screening.
No prior history of malignancy within 2 years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within 3 years
Subjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed > 2 years ago that has undergone potentially curative therapy with no evidence of disease for the last >= 2 years and that is deemed by the investigator to be at a low risk of recurrence
Patients with prior malignancy and treated with no evidence of active disease, and more than 2 years from initial diagnosis are eligible
History of other malignancy within the last 3 years (with exceptions).
Participants with a history of other malignancy within 5 years prior to screening
Previous malignancy within 2 years of the first dose of study drugs, except tumors totally resected and/or not requiring therapy
A history of other malignancy =< 5 years previous which would preclude endocrine treatment of their cancer
No active prior malignancy within 3 years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage 0 chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between 3-5 years, special consideration can be requested; in these cases, if the risk of recurrence at 5 years is less than 20%, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principal investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least 5 years will be eligible
Prior malignancy (EXCEPTION: diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy)
Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
Previous other malignancies unless they have undergone curative intent therapy for that malignancy and (1) have had no evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less than or equal to 20% at 5 years)
Previous chemotherapy for any malignancy, if given within three years of registration
Other malignancy within five years, except the following may be eligible:
No chemotherapy for a malignancy in the last 5 years
Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
Malignancy within the last 3 years
Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
Patients with a history of another malignancy within 5 years of study enrollment
Subjects with active other malignancy diagnosed in the past 3 years (excepting in situ tumors)
Individuals with a history of a previous malignancy are ineligible; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolled
History of other malignancy within 2 years prior to screening
Presence of malignancy other than the study indication under this trial within 3 years of study enrollment
History of other malignancy within the last 5 years
Have a concurrent malignancy or had another malignancy within 5 years (?5 years) of study enrollment.
History of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous 2 years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past 2 years will be allowed.
Diagnosed with another malignancy within the past 3 years
Have prior malignancy active within the previous 2 years;
Dose Expansion Phase only: diagnosis of any other malignancy within 2 years prior to registration.
History of other malignancy with the past 2 years with some exceptions
Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).
Any active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years
History of other malignancy within the past 3 years with the following exceptions:
There is any evidence of other malignancy being present within the last three years;
Patient has a history of hematological malignancy within the last 5 years prior to study entry
History of another malignancy within 3 years
Participants with a previous malignancy within the past 3 years
Subjects with history of other malignancy within past 5 years (with exceptions)
Other malignancy within the last 5 years
Any other current or previous malignancy within 3 years except protocol allowed malignancies
Active malignancy of metastatic potential other than the known carcinoid or pancreatic NET within the past three years
Other malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.
Any prior history of hematologic malignancy (other than CTCL) within past 5 years
Other malignancy within five years, except that the following may be eligible:
Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
Presence of malignancy other than the study indication under this trial within 5 years of study enrollment
History of metastatic malignancy in the preceding 2 years
Active treatment/chemotherapy for another primary malignancy within the past 5 years
Subjects with no additional active malignancy within the last 3 years
Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
History of metastatic malignancy in the preceding 2 years
Diagnosed with another primary malignancy in the past 3 years
Diagnosis of another malignancy within 2 years before first dose of study treatment.
History of prior malignancy within 3 years; patients who are considered no evidence of disease (NED) from a malignancy may be considered on a case by case basis
Other malignancy within the last 5 years (few exceptions apply);
Patients with a prior malignancy allowed if > 5 years ago with no current evidence of disease
Active or recent second malignancies unless they have undergone potentially curative therapy for that malignancy and (1) have had no evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less than or equal to 20% at 5 years)
Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
History of other active malignancy within the prior 2 years
Has a history of a malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years
Patients with evidence of another malignancy (exclusive of a skin cancer that requires only local treatment);\r\n* Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible\r\n* Patients with prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible
Patients with another malignancy within the past 5 years
Presence of any other malignancy or history of prior malignancy within 5 years of study entry; within 5 years, patients treated for stage I or II cancers are eligible provided they have a life expectancy > 5 years in relation to this prior malignancy; the 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer
Another current or previous malignancy within 2 years of study entry unless approved by the sponsor
Current or previous other malignancy within 2 years of study entry without sponsor approval
History of another malignancy within 2 years prior to starting study treatment
History (within 2 years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small (<5% in 2 years in the judgment of the investigator).
Patients with a completely treated prior malignancy with no evidence of disease for ?3 years are eligible
Active malignancy other than SCLC within the previous 5 years
History of another malignancy within the previous 5 years;
History of previous systemic chemotherapy unless given curatively for other malignancy now > 5 years without evidence of recurrence
Research participants with presence of other active malignancy within 2 years of study entry; participants with history of prior malignancy treated with curative intent who achieved complete remission (CR) more than 2 years before study entry are eligible; this exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer
Pathologically (histologically or cytologically) proven diagnosis of solid tumor malignancy within 5 years prior to Step 2 registration; if the original histologic proof of malignancy is greater than 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis)
Participants has a history of hematological malignancy within the last 5 years prior to study entry
Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; if the original histologic proof of malignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)
Patients who have received chemotherapy for a malignancy in the past 5 years
Another malignancy within 3 years
history of any other primary malignancy diagnosed within the past 5 years
Any other current or previous malignancy within the past 5 years
Patient has an active malignancy of metastatic potential other than the known NE tumor for the past 3 years
History of a prior malignancy within past 5 years are excluded unless they have been disease free for 3 or more years
Has history of other active malignancy within 3 years prior to enrollment, except:
Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
Criteria 5, History of other malignancy within the past 5 years prior to enrollment with some exceptions, as outlined in the protocol.
History of other malignancy within the past 3 years
